Data for this study were sourced from 4 active treatment arms of 4 randomized, controlled trials conducted by the National Institutes of Health in the United States between 2006 and 2018.
Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.
In a case-control study, researchers assessed the potential link between late-onset depression and the risk of developing major cognitive disorder.
Reddit posts from forums discussing self-harm were used to characterize and quantify the addiction language and to evaluate the extent to which individuals who engage in self-harm feel they are suffering from an addiction.
This retrospective cohort study evaluated patient data from patients aged 50 years or older who received an acute course of ECT between 2011 and 2019 and were evaluated for cognition and depression outcomes on the basis of baseline cognitive function.
Researchers compared the effects of 4 contemporary ablative neurosurgical procedures on treatment-resistant psychiatric symptoms.
Major depressive episodes reduce visual contrast suppression among patients with depressive disorders, a study shows.
This genome-wide associated study expanded on the gene-environment correlation for childhood maltreatment and causal relationship between childhood maltreatment and health.
Psilocybin has been shown to have antidepressant properties. With direct comparisons between psilocybin and established treatments for depression lacking, the study researchers looked at psilocybin and escitalopram.
While neurological and psychiatric sequelae of COVID-19 have been reported, more data are needed to adequately assess the effects of COVID-19 on brain health.